Myelodysplastic syndromes (MDS) are treated based on type and risk assessment, but traditional therapies may not work for everyone. Clinical trials offer a way to explore emerging treatments and ...

Patients with MDS report more symptoms than physicians, indicating a communication gap in symptom assessment. Allogeneic hematopoietic stem cell transplantation is the only cure but is limited to ...

Dr. Shah was compensated by BMS for his participation. Photo Credit: Shutterstock As you age, feeling tired or short of breath may be dismissed as a part of getting older, but it’s important to talk ...

The expert panel looks to future treatment management for patients with myelodysplastic syndrome. Ryan Haumschild, PharmD, MS, MBA: I want to think about the future. How is the future changing? Dr ...

Fatigue is very common in myelodysplastic syndromes (MDS) because anemia — low red blood cells — reduces oxygen delivery throughout your body, leaving you exhausted even after a full night’s sleep.

Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that the first real-world evidence study ...

Centers for Medicare & Medicaid Services is considering expanding the national coverage determination for allogeneic hematopoietic stem cell transplants using bone marrow or peripheral blood stem cell ...

Credit: Getty Images. The approval was based on data from the pivotal phase 3 COMMANDS trial that compared luspatercept to epoetin alfa in 356 patients with anemia and lower-risk MDS. The Food and ...

While infections pose a risk for morbidity and mortality among patients with MDS, more needs to be studied about the topic, researchers urged. Patients with myelodysplastic syndromes (MDS) may ...

Please provide your email address to receive an email when new articles are posted on . Most patients with newly diagnosed high-risk myelodysplastic syndrome do not receive guideline-recommended ...

Credit: Geron. The approval was based on data from the phase 2/3 IMerge study. The Food and Drug Administration (FDA) has approved Rytelo ™ (imetelstat) for the treatment of adult patients with low- ...